Skip to main content

Ligand Pharmaceuticals Inc. (LGND)

NASDAQ: LGND · IEX Real-Time Price · USD
155.32 1.02 (0.66%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap2.60B
Revenue (ttm)274.65M
Net Income (ttm)68.32M
Shares Out16.71M
EPS (ttm)4.05
PE Ratio38.39
Forward PE30.96
Dividendn/a
Ex-Dividend Daten/a
Volume61,311
Open154.70
Previous Close154.30
Day's Range153.39 - 156.56
52-Week Range89.18 - 219.75
Beta1.03
AnalystsBuy
Price Target211.71 (+36.3%)
Earnings DateNov 9, 2021

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treat...

IndustryBiotechnology
IPO DateNov 18, 1992
CEOJohn Higgins
Employees155
Stock ExchangeNASDAQ
Ticker SymbolLGND
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for LGND stock is "Buy." The 12-month stock price forecast is 211.71, which is an increase of 36.31% from the latest price.

Price Target
$211.71
(36.31% upside)
Analyst Consensus: Buy

News

Ligand's (LGND) Drug-Developing Technologies Holds Potential

Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.

1 week ago - Zacks Investment Research

Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb

Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.

4 weeks ago - Zacks Investment Research

Ligand Pharmaceuticals (LGND) Beats Q3 Earnings and Revenue Estimates

Ligand (LGND) delivered earnings and revenue surprises of 54.90% and 7.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Ligand Reports Third Quarter 2021 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand Reports Third Quarter 2021 Financial Results

4 weeks ago - Business Wire

Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company

4 weeks ago - Business Wire

5 Biotech Stocks With 105% to 386% Upside, According to Wall Street

Based on analysts' loftiest price targets, these drugmakers could double to nearly quintuple investors' money over the next 12 months.

Other symbols:CRSPICPTNVAXVXRT
1 month ago - The Motley Fool

Ligand to Report Third Quarter Financial Results on November 9, 2021

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report Third Quarter Financial Results on November 9, 2021

1 month ago - Business Wire

Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand's BEPro...

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic using Ligand's BEPro Technology™

1 month ago - Business Wire

Helping Your Kid Pay for College? Check Out This Podcast.

And a look at stocks that provided great lessons.

Other symbols:BBYMSFTSBUX
1 month ago - The Motley Fool

Ligand's Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Ref...

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China's Natio...

3 months ago - Business Wire

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study...

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

3 months ago - Business Wire

New Strong Sell Stocks for August 5th

AZRX, GHL, HEES, LGND, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2021.

Other symbols:GHLHEESPOLY
4 months ago - Zacks Investment Research

Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut

Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.

4 months ago - Zacks Investment Research

Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Top Estimates

Ligand (LGND) delivered earnings and revenue surprises of 12.41% and 15.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Ligand Reports Second Quarter 2021 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand Reports Second Quarter 2021 Financial Results

4 months ago - Business Wire

Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower t...

PALO ALTO, Calif., July 28, 2021 /PRNewswire/ -- Landing AI™ announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to incorporate LandingLens™ into Ligan...

4 months ago - PRNewsWire

Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy?

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly...

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Partner Jazz Pharmaceuticals Launches RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458

4 months ago - Business Wire

Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in ...

SAN DIEGO--(BUSINESS WIRE)---- $LGND--Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes

4 months ago - Business Wire

Ligand to Report Second Quarter Financial Results on July 29, 2021

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report Second Quarter Financial Results on July 29, 2021

4 months ago - Business Wire

Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors

4 months ago - Business Wire

Ligand (LGND) Moves 3.1% Higher: Will This Strength Last?

Ligand (LGND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...

5 months ago - Zacks Investment Research

LENZ Therapeutics Debuts With $47 Million Series A Financing

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for presbyopia, today emerged from st...

5 months ago - Business Wire

Ligand (LGND) Down 14% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research